Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy.

Zhang Q, Zhang Y, Diamond S, Boer J, Harris JJ, Li Y, Rupar M, Behshad E, Gardiner C, Collier P, Liu P, Burn T, Wynn R, Hollis G, Yeleswaram S.

Drug Metab Dispos. 2014 Oct;42(10):1656-62. doi: 10.1124/dmd.114.058883. Epub 2014 Jul 25.

2.

Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke's encephalopathy.

Hazell AS, Afadlal S, Cheresh DA, Azar A.

Neurosci Lett. 2017 Mar 6;642:163-167. doi: 10.1016/j.neulet.2017.01.041. Epub 2017 Jan 18.

PMID:
28109775
3.

Putamina involvement in Wernicke encephalopathy induced by Janus Kinase 2 inhibitor.

Rodríguez-Pardo J, Puertas-Muñoz I, Martínez-Sánchez P, Díaz de Terán J, Pulido-Valdeolivas I, Fuentes B.

Clin Neuropharmacol. 2015 May-Jun;38(3):117-8. doi: 10.1097/WNF.0000000000000083.

PMID:
25970282
4.

Interaction of 2,4-Diaminopyrimidine-Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters.

Giacomini MM, Hao J, Liang X, Chandrasekhar J, Twelves J, Whitney JA, Lepist EI, Ray AS.

Drug Metab Dispos. 2017 Jan;45(1):76-85. Epub 2016 Nov 1. Erratum in: Drug Metab Dispos. 2017 Nov;45(11):1146-1147.

5.

A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers.

Zhang M, Xu CR, Shamiyeh E, Liu F, Yin JY, von Moltke LL, Smith WB.

J Clin Pharmacol. 2014 Apr;54(4):415-21. doi: 10.1002/jcph.218. Epub 2013 Nov 16.

PMID:
24165976
6.

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.

Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M.

Blood Cancer J. 2015 Aug 7;5:e335. doi: 10.1038/bcj.2015.63.

7.

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA.

Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.

PMID:
28602585
8.

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A.

JAMA Oncol. 2015 Aug;1(5):643-51. doi: 10.1001/jamaoncol.2015.1590.

PMID:
26181658
9.

[Familial Wernicke's-like encephalopathy].

Miyajima H, Kono S.

Rinsho Shinkeigaku. 2010 Nov;50(11):855-7. Japanese.

PMID:
21921471
10.

Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers.

Zhang M, Xu C, Ma L, Shamiyeh E, Yin J, von Moltke LL, Smith WB.

Clin Pharmacol Drug Dev. 2015 Jul;4(4):315-21. doi: 10.1002/cpdd.161. Epub 2014 Oct 27.

PMID:
27136912
11.

Thyrotoxicosis associated Wernicke's encephalopathy.

Bonucchi J, Hassan I, Policeni B, Kaboli P.

J Gen Intern Med. 2008 Jan;23(1):106-9. Epub 2007 Nov 17.

12.

Early diagnosis of pediatric Wernicke's encephalopathy.

Vasconcelos MM, Silva KP, Vidal G, Silva AF, Domingues RC, Berditchevsky CR.

Pediatr Neurol. 1999 Apr;20(4):289-94. Review.

PMID:
10328278
13.

[Wernicke's encephalopathy].

Andersson JE.

Ugeskr Laeger. 1996 Feb 12;158(7):898-901. Review. Danish.

PMID:
8638325
14.

Wernicke's encephalopathy: expanding the diagnostic toolbox.

Lough ME.

Neuropsychol Rev. 2012 Jun;22(2):181-94. doi: 10.1007/s11065-012-9200-7. Epub 2012 May 11. Review.

PMID:
22577001
15.

Thiamine deficiency and Wernicke's encephalopathy in AIDS.

Butterworth RF, Gaudreau C, Vincelette J, Bourgault AM, Lamothe F, Nutini AM.

Metab Brain Dis. 1991 Dec;6(4):207-12.

PMID:
1812394
16.

Wernicke's encephalopathy in a non-alcoholic man: case report and brief review.

Munir A, Hussain SA, Sondhi D, Ameh J, Rosner F.

Mt Sinai J Med. 2001 May;68(3):216-8.

PMID:
11373696
17.

Thiamine deficiency and beriberi features in a patient with hyperemesis gravidarum.

Indraccolo U, Gentile G, Pomili G, Luzi G, Villani C.

Nutrition. 2005 Sep;21(9):967-8.

PMID:
15979284
18.

A case report of Wernicke's encephalopathy in a pediatric patient with anorexia nervosa--restricting type.

Peters TE, Parvin M, Petersen C, Faircloth VC, Levine RL.

J Adolesc Health. 2007 Apr;40(4):376-83. Epub 2007 Feb 5.

PMID:
17367738
19.

Histamine-mediated neuronal death in a rat model of Wernicke's encephalopathy.

Langlais PJ, Zhang SX, Weilersbacher G, Hough LB, Barke KE.

J Neurosci Res. 1994 Aug 1;38(5):565-74.

PMID:
7529327
20.

Mutations in a thiamine-transporter gene and Wernicke's-like encephalopathy.

Kono S, Miyajima H, Yoshida K, Togawa A, Shirakawa K, Suzuki H.

N Engl J Med. 2009 Apr 23;360(17):1792-4. doi: 10.1056/NEJMc0809100. No abstract available.

Supplemental Content

Support Center